Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Relapsed NLPHL
NCT02626884Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Aug 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), sponsored by University of Cologne. Started Aug 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)
Beyond the preview
Go deeper on NCT02626884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626884.